Payment overview · 2025
General Payments
$213.14
11 reported records · 6 companies
Healthcare provider profile · identity verified
John Tran, DO
Allopathic & Osteopathic Physicians|Family Medicine · ALTUS, OK · NPI 1285677203
Verified facts
What the public records show
CMS Open Payments records show John Tran, DO received $213.14 in general payments during 2025 across 11 reported records.
Lilly USA, LLC accounted for 41.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.43 | 41.5% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.30 | 18.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.94 | 16.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.86 | 8.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.70 | 7.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.91 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $213.14 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $88.43 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.74 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 181 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
181 | 32 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 564 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 544 | 119 |
| Lisinopril | Lisinopril | 433 | 114 |
| Potassium Chloride | Potassium Chloride | 420 | 73 |
| Gabapentin | Gabapentin | 386 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 371 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 346 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 81 |
| Furosemide | Furosemide | 304 | 72 |
| Losartan Potassium | Losartan Potassium | 285 | 70 |
| Omeprazole | Omeprazole | 268 | 59 |
| Metformin Hcl | Metformin Hcl | 262 | 68 |
| Lorazepam | Lorazepam | 253 | 19 |
| Simvastatin | Simvastatin | 228 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 215 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 72 |
| Sertraline Hcl | Sertraline Hcl | 194 | 31 |
| Tramadol Hcl | Tramadol Hcl | 190 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 183 | 15 |
| Eliquis | Apixaban | 181 | 32 |
| Trazodone Hcl | Trazodone Hcl | 172 | 35 |
| Allopurinol | Allopurinol | 146 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 29 |
| Donepezil Hcl | Donepezil Hcl | 142 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 118 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 31 |
| Azithromycin | Azithromycin | 106 | 84 |
| Carvedilol | Carvedilol | 105 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 21 |
| Clonazepam | Clonazepam | 98 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 22 |
| Divalproex Sodium | Divalproex Sodium | 93 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 92 | 49 |
| Jardiance | Empagliflozin | 88 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 88 | 32 |
| Torsemide | Torsemide | 87 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 81 | 21 |
| Linzess | Linaclotide | 75 | suppressed |
| Memantine Hcl | Memantine Hcl | 75 | 11 |
| Meloxicam | Meloxicam | 74 | 22 |
| Ibuprofen | Ibuprofen | 73 | 22 |
| Loperamide | Loperamide Hcl | 71 | 11 |
| Celecoxib | Celecoxib | 70 | 15 |
| Ezetimibe | Ezetimibe | 67 | 19 |
| Famotidine | Famotidine | 65 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 12 |
| Trimethoprim | Trimethoprim | 62 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 61 | 17 |
| Ozempic | Semaglutide | 61 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 11 |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Trulicity | Dulaglutide | 58 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 15 |
| Clonidine Hcl | Clonidine Hcl | 55 | 15 |
| Levetiracetam | Levetiracetam | 55 | 12 |
| Mupirocin | Mupirocin | 55 | 35 |
| Buspirone Hcl | Buspirone Hcl | 54 | suppressed |
| Glipizide | Glipizide | 54 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 53 | suppressed |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Cephalexin | Cephalexin | 52 | 35 |
| Clozapine | Clozapine | 51 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 51 | 21 |
| Risperidone | Risperidone | 51 | suppressed |
| Amoxicillin | Amoxicillin | 50 | 42 |
| Alprazolam | Alprazolam | 49 | 12 |
| Ondansetron Odt | Ondansetron | 49 | 12 |
| Baclofen | Baclofen | 48 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | suppressed |
| Pregabalin | Pregabalin | 45 | 11 |
| Spironolactone | Spironolactone | 45 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 11 |
| Latanoprost | Latanoprost | 43 | suppressed |
| Bumetanide | Bumetanide | 42 | suppressed |
| Atenolol | Atenolol | 41 | 13 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Tradjenta | Linagliptin | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 12 |
| Nystatin | Nystatin | 38 | 22 |
| Fentanyl | Fentanyl | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Premarin | Estrogens, Conjugated | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 12 |
| Roflumilast | Roflumilast | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 18 | suppressed |
| Lamotrigine Odt | Lamotrigine | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 11 |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 12 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Novolog | Insulin Aspart | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Travoprost | Travoprost | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Lamivudine-Zidovudine | Lamivudine/Zidovudine | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Exelon | Rivastigmine | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $213.14 · 11 records | Lilly USA, LLC | BREZTRI, ELIQUIS, GEMTESA, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error